Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Get SEC filing alerts via email and in your feed for LIXTE BIOTECHNOLOGY HOLDINGS, INC.

LIXT LIXTW

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

About LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies, primarily focusing on inhibitors of protein phosphatase 2A, such as LB-100. Its pipeline aims to enhance existing treatments like chemotherapy and immunotherapy across various cancers. The company advances its products through clinical trials, seeking regulatory approval and strategic partnerships, with a strong emphasis on innovative mechanisms and intellectual property protection.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from LIXTE BIOTECHNOLOGY HOLDINGS, INC.

1
1
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Lixte Biotechnology Reports $1.99M Net Loss and No Revenue for Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Lixte Biotechnology Reports $6 Million Net Loss and Acquires Liora Technologies

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Lixte Biotechnology Reports $3.47 Million Net Loss in Q3 2025, Cash Reserves Increase to $2.89 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Lixte Biotechnology Reports Q2 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Lixte Biotechnology Reports Decreased Net Loss and Improved Cash Position for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Lixte Biotechnology Reports $3.6 Million Net Loss for 2024, Seeks Additional Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Lixte Biotechnology Reports No Revenue, Net Loss in Q3 2024, Cites Need for Additional Capital

Via official filing (AI summary) | over 1 year ago | 0 comments